BL
KZIA

Bleichroeder LP’s Kazia Therapeutics KZIA Stock Holding History

Bleichroeder LP’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.63M Hold
400,000
– – 1.01% 15
2026
Q1 		$2.98M Hold
400,000
– – 0.51% 27
2025
Q4 		$2.76M Buy
+400,000
New +$3.41M 0.49% 27

Other funds holding KZIA

BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Bleichroeder LP's KZIA Position: Q2 2026 in Review

Bleichroeder LP held its Kazia Therapeutics (KZIA) position steady in Q2 2026 at 400,000 shares worth $5.63M. The position accounts for 1.01% of the portfolio, ranked #15.

Bleichroeder LP first reported a position in KZIA in Q4 2025 and has held it in 3 quarters since. 36 funds tracked by Wall St. Rank hold KZIA as of Q2 2026.

  • Bleichroeder LP held 400,000 shares of Kazia Therapeutics worth $5.63M as of Q2 2026.
  • Bleichroeder LP left its Kazia Therapeutics share count unchanged in Q2 2026.
  • Kazia Therapeutics made up 1.01% of Bleichroeder LP's portfolio in Q2 2026, its #15 holding.
  • Bleichroeder LP first reported a position in Kazia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 36 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2026.

Based on Bleichroeder LP's 13F filing for Q2 2026, filed 13 Aug 2026.